🌟 Discover the latest from the FDA’s CDER: 9 innovative drugs for Q1!
🧴Berdazimer (Zelsuvmi) tackles topical molluscum contagiosum with nitric oxide release.
đź’‰Cefepime/enmetazobactam (Exblifep) combines forces for urinary tract infection relief.
đź’‰LetibotulinumtoxinA (Letybo) smooths glabellar lines with botulinum neurotoxin.
đź’‰Tislelizumab (Tivembra) fights esophageal squamous cell carcinoma with PD-1 mAb technology.
đź’ŠResmetirom (Rezdiffra), a thyroid hormone receptor beta agonist, battles nonalcoholic steatohepatitis.
đź’ŠAprocitentan (Tryvio) manages hypertension through endothelin receptor antagonism.
đź’ŠGivinostat (Duvyzat) aims at Duchenne muscular dystrophy with HDAC inhibition.
đź’‰Sotatercept (Winrevair), an activin inhibitor, offers hope for pulmonary arterial hypertension patients.
đź’ŠVadadustat (Vafseo) addresses CKD-related anemia in dialysis patients as an oral HIF-PH inhibitor.

Explore these groundbreaking treatments! Our appreciation to Chris De Savi for the great compilation!